中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 1
Jan.  2023
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2023  >  39(1): 211-217

Application and potential value of endogenous lipid mediators in liver failure

DOI: 10.3969/j.issn.1001-5256.2023.01.033
  • 1.

    Graduate School of Guangxi University of Chinese Medicine, Nanning 530200, China

  • 2.

    Second Ward of Hepatology, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning 530023, China

Research funding:

National Natural Science Foundation of China (81960841);

National Science and Technology Major Project (2018ZX10725505-001-011);

Guangxi Science and technology project (2020GXNSFAA297098);

Guangxi University of Traditional Chinese Medicine Graduate Innovation project (YCXJ2021034)

More Information
  • Corresponding author: LONG Fuli, longfuli005@163.com (ORCID: 0000-0003-1196-2697)
  • Received Date: 2022-05-11
  • Accepted Date: 2022-06-16
  • Published Date: 2023-01-20
    Abstract
  • Liver failure is a common end-stage liver disease syndrome in clinical practice characterized by massive necrosis of hepatocytes leading to rapid liver failure, and it is currently believed that excessive inflammation and immune response are the core mechanisms of this disease. Endogenous lipid mediators are involved in the regulation of a variety of inflammatory processes, including initiation, maintenance, and regression, and eicosanoids and pro-decomposition lipid mediators, as well as their complex metabolic pathways and transduction signals, play a key role in the regulation of these processes. This article reviews the key role of endogenous lipid mediators in the pathophysiological mechanism of inflammation and immune dysfunction in liver failure and the potential significance and new therapeutic opportunities of lipid immune pathway in liver failure, in order to provide new ideas for the clinical diagnosis and treatment of liver failure.

     

    • FullText(HTML)
  • loading
    • References(47)
  • [1]
    LEVY BD, CLISH CB, SCHMIDT B, et al. Lipid mediator class switching during acute inflammation: signals in resolution[J]. Nat Immunol, 2001, 2(7): 612-619. DOI: 10.1038/89759.
    [2]
    von MOLTKE J, TRINIDAD NJ, MOAYERI M, et al. Rapid induction of inflammatory lipid mediators by the inflammasome in vivo[J]. Nature, 2012, 490(7418): 107-111. DOI: 10.1038/nature11351.
    [3]
    MOUCHLIS VD, DENNIS EA. Phospholipase A2 catalysis and lipid mediator lipidomics[J]. Biochim Biophys Acta Mol Cell Biol Lipids, 2019, 1864(6): 766-771. DOI: 10.1016/j.bbalip.2018.08.010.
    [4]
    LEUTI A, FAZIO D, FAVA M, et al. Bioactive lipids, inflammation and chronic diseases[J]. Adv Drug Deliv Rev, 2020, 159: 133-169. DOI: 10.1016/j.addr.2020.06.028.
    [5]
    BOSMA KJ, KAISER CE, KIMPLE ME, et al. Effects of arachidonic acid and its metabolites on functional beta-cell mass[J]. Metabolites, 2022, 12(4): 342. DOI: 10.3390/metabo12040342.
    [6]
    NI KD, LIU JY. The functions of cytochrome P450 ω-hydroxylases and the associated eicosanoids in inflammation-related diseases[J]. Front Pharmacol, 2021, 12: 716801. DOI: 10.3389/fphar.2021.716801.
    [7]
    KAUR B, SINGH P. Inflammation: Biochemistry, cellular targets, anti-inflammatory agents and challenges with special emphasis on cyclooxygenase-2[J]. Bioorg Chem, 2022, 121: 105663. DOI: 10.1016/j.bioorg.2022.105663.
    [8]
    AOKI T, NARUMIYA S. Prostaglandins and chronic inflammation[J]. Trends Pharmacol Sci, 2012, 33(6): 304-311. DOI: 10.1016/j.tips.2012.02.004.
    [9]
    CHIURCHIÙ V, LEUTI A, MACCARRONE M. Bioactive lipids and chronic inflammation: Managing the fire within[J]. Front Immunol, 2018, 9: 38. DOI: 10.3389/fimmu.2018.00038.
    [10]
    SERHAN CN. Pro-resolving lipid mediators are leads for resolution physiology[J]. Nature, 2014, 510(7503): 92-101. DOI: 10.1038/nature13479.
    [11]
    SERHAN CN, DALLI J, KARAMNOV S, et al. Macrophage proresolving mediator maresin 1 stimulates tissue regeneration and controls pain[J]. FASEB J, 2012, 26(4): 1755-1765. DOI: 10.1096/fj.11-201442.
    [12]
    WERZ O, GERSTMEIER J, LIBREROS S, et al. Human macrophages differentially produce specific resolvin or leukotriene signals that depend on bacterial pathogenicity[J]. Nat Commun, 2018, 9(1): 59. DOI: 10.1038/s41467-017-02538-5.
    [13]
    ASATRYAN A, BAZAN NG. Molecular mechanisms of signaling via the docosanoid neuroprotectin D1 for cellular homeostasis and neuroprotection[J]. J Biol Chem, 2017, 292(30): 12390-12397. DOI: 10.1074/jbc.R117.783076.
    [14]
    CHIURCHIÙ V, LEUTI A, DALLI J, et al. Proresolving lipid mediators resolvin D1, resolvin D2, and maresin 1 are critical in modulating T cell responses[J]. Sci Transl Med, 2016, 8(353): 353ra111. DOI: 10.1126/scitranslmed.aaf7483.
    [15]
    SERHAN CN, LEVY BD. Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators[J]. J Clin Invest, 2018, 128(7): 2657-2669. DOI: 10.1172/JCI97943.
    [16]
    PEREZ-HERNANDEZ J, CHIURCHIÙ V, PERRUCHE S, et al. Regulation of T-Cell immune responses by pro-resolving lipid mediators[J]. Front Immunol, 2021, 12: 768133. DOI: 10.3389/fimmu.2021.768133.
    [17]
    SUCIU M, GRUIA AT, NICA DV, et al. Acetaminophen-induced liver injury: Implications for temporal homeostasis of lipid metabolism and eicosanoid signaling pathway[J]. Chem Biol Interact, 2015, 242: 335-344. DOI: 10.1016/j.cbi.2015.10.019.
    [18]
    ABDEL-GABER SA, IBRAHIM MA, AMIN EF, et al. Effect of selective versus non-selective cyclooxygenase inhibitors on ischemia-reperfusion-induced hepatic injury in rats[J]. Life Sci, 2015, 134: 42-48. DOI: 10.1016/j.lfs.2015.04.025.
    [19]
    HAN C, LI G, LIM K, et al. Transgenic expression of cyclooxygenase-2 in hepatocytes accelerates endotoxin-induced acute liver failure[J]. J Immunol, 2008, 181(11): 8027-8035. DOI: 10.4049/jimmunol.181.11.8027.
    [20]
    MISAWA H, OHASHI W, TOMITA K, et al. Prostacyclin mimetics afford protection against lipopolysaccharide/d-galactosamine-induced acute liver injury in mice[J]. Toxicol Appl Pharmacol, 2017, 334: 55-65. DOI: 10.1016/j.taap.2017.09.003.
    [21]
    SREERAMKUMAR V, FRESNO M, CUESTA N. Prostaglandin E2 and T cells: Friends or foes?[J]. Immunol Cell Biol, 2012, 90(6): 579-586. DOI: 10.1038/icb.2011.75.
    [22]
    NORTH TE, BABU IR, VEDDER LM, et al. PGE2-regulated wnt signaling and N-acetylcysteine are synergistically hepatoprotective in zebrafish acetaminophen injury[J]. Proc Natl Acad Sci U S A, 2010, 107(40): 17315-17320. DOI: 10.1073/pnas.1008209107.
    [23]
    WANG H, ZHANG R, ZHU Y, et al. Microsomal prostaglandin E synthase 2 deficiency is resistant to acetaminophen-induced liver injury[J]. Arch Toxicol, 2019, 93(10): 2863-2878. DOI: 10.1007/s00204-019-02543-1.
    [24]
    NISHIZAWA N, ITO Y, ESHIMA K, et al. Inhibition of microsomal prostaglandin E synthase-1 facilitates liver repair after hepatic injury in mice[J]. J Hepatol, 2018, 69(1): 110-120. DOI: 10.1016/j.jhep.2018.02.009.
    [25]
    WANG J, LIU Y, DING H, et al. Mesenchymal stem cell-secreted prostaglandin E2 ameliorates acute liver failure via attenuation of cell death and regulation of macrophage polarization[J]. Stem Cell Res Ther, 2021, 12(1): 15. DOI: 10.1186/s13287-020-02070-2.
    [26]
    ITO S, ITO Y, KATAGIRI H, et al. Leukotriene B4/leukotriene B4 receptor pathway is involved in hepatic microcirculatory dysfunction elicited by endotoxin[J]. Shock, 2008, 30(1): 87-91. DOI: 10.1097/shk.0b013e31815d06a1.
    [27]
    LI L, LIU YR, GAO S, et al. Inhibition of 5-lipoxygenase pathway attenuates acute liver failure by inhibiting macrophage activation[J]. J Immunol Res, 2014, 2014: 697560. DOI: 10.1155/2014/697560.
    [28]
    TITOS E, CLÀRIA J, PLANAGUMÀ A, et al. Inhibition of 5-lipoxygenase-activating protein abrogates experimental liver injury: role of Kupffer cells[J]. J Leukoc Biol, 2005, 78(4): 871-878. DOI: 10.1189/jlb.1204747.
    [29]
    QIN XB, ZHANG RZ, WU C, et al. Immunotherapy for acute-on-chronic liver failure[J]. J Clin Hepatol, 2021, 37(11): 2696-2700. DOI: 10.3969/j.issn.1001-5256.2021.11.046.

    覃小宾, 张荣臻, 吴聪, 等. 慢加急性肝衰竭的免疫治疗[J]. 临床肝胆病杂志, 2021, 37(11): 2696-2700. DOI: 10.3969/j.issn.1001-5256.2021.11.046.
    [30]
    LÓPEZ-VICARIO C, CHECA A, URDANGARIN A, et al. Targeted lipidomics reveals extensive changes in circulating lipid mediators in patients with acutely decompensated cirrhosis[J]. J Hepatol, 2020, 73(4): 817-828. DOI: 10.1016/j.jhep.2020.03.046.
    [31]
    ALCARAZ-QUILES J, CASULLERAS M, OETTL K, et al. Oxidized albumin triggers a cytokine storm in leukocytes through P38 mitogen-activated protein kinase: Role in systemic inflammation in decompensated cirrhosis[J]. Hepatology, 2018, 68(5): 1937-1952. DOI: 10.1002/hep.30135.
    [32]
    HUANG XP, WANG Y, CHEN L, et al. Elevated serum prostaglandin E2 predicts the risk of infection in hepatitis B virus-related acute-on-chronic liver failure patients[J]. Asian Pac J Trop Med, 2017, 10(9): 916-920. DOI: 10.1016/j.apjtm.2017.08.008.
    [33]
    MAINI AA, BECARES N, CHINA L, et al. Monocyte dysfunction in decompensated cirrhosis is mediated by the prostaglandin E2-EP4 pathway[J]. JHEP Rep, 2021, 3(6): 100332. DOI: 10.1016/j.jhepr.2021.100332.
    [34]
    WANG Y, CHEN C, QI J, et al. Altered PGE2-EP2 is associated with an excessive immune response in HBV-related acute-on-chronic liver failure[J]. J Transl Med, 2019, 17(1): 93. DOI: 10.1186/s12967-019-1844-0.
    [35]
    JIANG X, LI Z, JIANG S, et al. Lipoxin A4 exerts protective effects against experimental acute liver failure by inhibiting the NF-κB pathway[J]. Int J Mol Med, 2016, 37(3): 773-780. DOI: 10.3892/ijmm.2016.2483.
    [36]
    CHEN X, GONG X, JIANG R, et al. Resolvin D1 attenuates CCl4-induced acute liver injury involving up-regulation of HO-1 in mice[J]. Immunopharmacol Immunotoxicol, 2016, 38(2): 61-67. DOI: 10.3109/08923973.2015.1115517.
    [37]
    SORDI R, CHIAZZA F, COLLOTTA D, et al. Resolvin D1 attenuates the organ injury associated with experimental hemorrhagic shock[J]. Ann Surg, 2021, 273(5): 1012-1021. DOI: 10.1097/SLA.0000000000003407.
    [38]
    MURAKAMI T, SUZUKI K, TAMURA H, et al. Suppressive action of resolvin D1 on the production and release of septic mediators in D-galactosamine-sensitized endotoxin shock mice[J]. Exp Ther Med, 2011, 2(1): 57-61. DOI: 10.3892/etm.2010.170.
    [39]
    CLÀRIA J, STAUBER RE, COENRAAD MJ, et al. Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure[J]. Hepatology, 2016, 64(4): 1249-1264. DOI: 10.1002/hep.28740.
    [40]
    ZHANG IW, CURTO A, LÓPEZ-VICARIO C, et al. Mitochondrial dysfunction governs immunometabolism in leukocytes of patients with acute-on-chronic liver failure[J]. J Hepatol, 2022, 76(1): 93-106. DOI: 10.1016/j.jhep.2021.08.009.
    [41]
    CLÀRIA J, FLORES-COSTA R, DURAN-GVELL M, et al. Proresolving lipid mediators and liver disease[J]. Biochim Biophys Acta Mol Cell Biol Lipids, 2021, 1866(11): 159023. DOI: 10.1016/j.bbalip.2021.159023.
    [42]
    MOREAU R, CLÀRIA J, AGUILAR F, et al. Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF[J]. J Hepatol, 2020, 72(4): 688-701. DOI: 10.1016/j.jhep.2019.11.009.
    [43]
    GU J, LUO L, WANG Q, et al. Maresin 1 attenuates mitochondrial dysfunction through the ALX/cAMP/ROS pathway in the cecal ligation and puncture mouse model and sepsis patients[J]. Lab Invest, 2018, 98(6): 715-733. DOI: 10.1038/s41374-018-0031-x.
    [44]
    HECKER M, SOMMER N, FOCH S, et al. Resolvin E1 and its precursor 18R-HEPE restore mitochondrial function in inflammation[J]. Biochim Biophys Acta Mol Cell Biol Lipids, 2018, 1863(9): 1016-1028. DOI: 10.1016/j.bbalip.2018.06.011.
    [45]
    OKADA L, OLIVEIRA CP, STEFANO JT, et al. Omega-3 PUFA modulate lipogenesis, ER stress, and mitochondrial dysfunction markers in NASH - Proteomic and lipidomic insight[J]. Clin Nutr, 2018, 37(5): 1474-1484. DOI: 10.1016/j.clnu.2017.08.031.
    [46]
    YANG J, FERNÁNDEZ-GALILEA M, MARTÍNEZ-FERNÁNDEZ L, et al. Oxidative stress and non-alcoholic fatty liver disease: Effects of Omega-3 fatty acid supplementation[J]. Nutrients, 2019, 11(4). DOI: 10.3390/nu11040872.
    [47]
    KULKARNI AV, ANAND L, VYAS AK, et al. Omega-3 fatty acid lipid emulsions are safe and effective in reducing endotoxemia and sepsis in acute-on-chronic liver failure: An open-label randomized controlled trial[J]. J Gastroenterol Hepatol, 2021, 36(7): 1953-1961. DOI: 10.1111/jgh.15400.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1707) PDF downloads(62) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return